Financial Consequences of Improved Treatments for Colorectal Cancer

Seminars in Colon and Rectal Surgery

Volumn 19, Issue 4, 2008, Pages 247-252

  Wong, Yu Ning ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; ENOXAPARIN; FLUOROURACIL; FOLINIC ACID; GABAPENTIN; GRANISETRON; IRINOTECAN; ONDANSETRON; OXALIPLATIN; OXYCODONE; PREGABALIN; PROCHLORPERAZINE; WARFARIN;

ANTICOAGULANT THERAPY; ARTICLE; CANCER GRADING; CANCER PAIN; CANCER PATIENT; COLORECTAL CANCER; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DIABETIC NEUROPATHY; DRUG COST; HEALTH CARE ACCESS; HEALTH CARE COST; HEALTH INSURANCE; HIGH RISK PATIENT; MEDICARE; PATIENT ASSESSMENT; PATIENT CARE; PATIENT DECISION MAKING; REIMBURSEMENT; RISK BENEFIT ANALYSIS;

EID: 56349106964     PISSN: 10431489     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.scrs.2008.09.010     Document Type: Article

References (27)

1. Andre T., Boni C., Mounedji-Boudiaf L., et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350 23 (2004) 2343-2351
2. The NCCN Colon Cancer Clinical Practice Guidelines in Oncology (Version 1.2008). [DONE]© 2008 National Comprehensive Cancer Network, Inc. http://www.nccn.org Accessed April 30, 2008
3. Petrylak D.P., Tangen C.M., Hussain M.H.A., et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351 15 (2004) 1513-1520
4. Benson III A.B. New approaches to assessing and treating early-stage colon and rectal cancers: cooperative group strategies for assessing optimal approaches in early-stage disease. Clin Cancer Res 13 22 (2007) 6913s-6920s
5. Figueredo A., Charette M.L., Maroun J., et al. Adjuvant therapy for stage ii colon cancer: a systematic review from the Cancer Care Ontario Program in evidence-based care's gastrointestinal cancer disease site group. J Clin Oncol 22 16 (2004) 3395-3407
6. Colorectal Cancer Cancer Version 2.2008, in Practice Guidelines in Oncology. National Comprehensive Cancer Network (2007)
7. Hoffman J.M., Shah N.D., Vermeulen L.C., et al. Projecting future drug expenditures-2007. Am J Health Syst Pharm 64 3 (2007) 298-314
8. Medicare Part B Drugs and Oncology, Statement of Mark E. Miller, PhD, in Subcommittee on Health, House Ways and Means. Washington DC, 2006
9. Meropol N.J., and Schulman K.A. Perspectives on the cost of cancer care. J Clin Oncol 25 2 (2007) 169-170
10. Pauly M.V. Is high and growing spending on cancer treatment and prevention harmful to the United States economy?. J Clin Oncol 25 2 (2007) 171-174
11. Ramsey S.D. How should we pay the piper when he's calling the tune?. On the long-term affordability of cancer care in the United States. J Clin Oncol 25 2 (2007) 175-179
12. Banthin J.S., and Bernard D.M. Changes in financial burdens for health care: national estimates for the population younger than 65 years, 1996 to 2003. JAMA 296 22 (2006) 2712-2719
13. National Survey of Households Affected by Cancer: The USA Today/Kaiser Family Foundation/Harvard School of Public Health: Menlo Park, CA, 2006
14. Banthin J., and Bernard D. Out-of-pocket expenditures on health care and insurance premiums among the elderly population, 2003, in medical expenditures panel survey statistical brief #122 (2006), Agency for Health Care Research and Quality, Washington, DC
15. Himmelstein DU, Warren E, Thorne D, et al: MarketWatch: illness and injury as contributors to bankruptcy. Health Aff 2005:hlthaff.w5.63
16. www.medicare.gov accessed 4/22/2008
17. Kaa K. Medicare challenges and solutions-reimbursement issues in treating the patient with colorectal cancer. J Manag Care Pharm 13 suppl 6C (2007) S19-S26
18. Friedman J.Y., Curtis L.H., Hammill B.G., et al. The Medicare Modernization Act and reimbursement for outpatient chemotherapy: do patients perceive changes in access to care?. Cancer 110 10 (2007) 2304-2312
19. Mays J.B., Neuman M.T., Cubanski J., et al. Estimates of Medicare beneficiaries' out of pocket drug spending in 2006 modeling the impact of MMMA, in The Medicare RX Drug Law (2004), The Henry J. Kaiser Family Foundation, Menlo Park CA
20. Gellad W.F., Huskamp H.A., Phillips K.A., et al. How The new Medicare drug benefit could affect vulnerable populations. Health Aff 25 1 (2006) 248-255
21. Schrag D., and Hanger M. Medical oncologists' views on communicating with patients about chemotherapy costs: a pilot survey. J Clin Oncol 25 2 (2007) 233-237
22. Piette J.D., Heisler M., and Wagner T.H. Cost-related medication underuse: do patients with chronic illnesses tell their doctors?. Arch Intern Med 164 16 (2004) 1749-1755
23. Kasiske B.L., Cohen D., Lucey M.R., et al. Payment for immunosuppression after organ transplantation. American Society of Transplantation. JAMA 283 18 (2000) 2445-2450
24. Hsu J., Price M., Huang J., et al. Unintended Consequences of caps on Medicare drug benefits. N Engl J Med 354 22 (2006) 2349-2359
25. Goldman D.P., Joyce G.F., Lawless G., et al. Benefit design and specialty drug use. Health Aff 25 5 (2006) 1319-1331
26. Bowman J., Rousseau A., Silk D., et al. Access to cancer drugs in Medicare Part D: formulary placement and beneficiary cost sharing in 2006. Health Aff 25 5 (2006) 1240-1248
27. Robinson J.C. Insurers' Strategies For Managing The Use And Cost Of Biopharmaceuticals. Health Aff 25 5 (2006) 1205-1217